Il sistema RANKL/RANK, osteoprotegerina e osteopontina in una coorte di soggetti affetti da poliartrite cronica. Studio preliminare

Translated title of the contribution: RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report

Giovanna Minenna, Simona D'Amore, Piera Maggiolini, Pasquale Scagliusi, Massimo D'Amore

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Recently, receptor activator of nuclear factor-kB ligand (RANKL), its receptor RANK, and the decoy receptor osteoprotegerin (OPG), have been identified as paracrine mediator of bone functions. The balance of RANKL/RANK and OPG is critical for osteoclastogenesis modulation and physiological bone remodeling. Osteopontin (OPN) is an extracellular glycosylate bone phosphoprotein and acts both as chemokine and cytochine. It is produced by osteoclast, macrophages, T cells, hematopoietic cells and vascular smooth muscle cells. It is present particularly at high concentration in the lamina limitans and cement line, suggesting its role in the initiation and termination of the bone turnover. Chronic arthritis are a group of rheumatic patologies characterized by periodical continuous or desultory use of corticosteroides. The main aims of this study are to valuate OPG, RANKL and OPN serum concentrations in patients affected by chronic arthritis and to compare the above results with those ones obtained by young healthy population. OPG, RANKL and OPN serum concentration has been measured by ELISA method both in 40 patients affected by chronic arthritis then in young healthy population of 81 subjects. The differences between the two considered groups have been analyzed using unpaired T-Student. The difference between the two groups is significant for considered variables: OPG: t=-6,54, p

Original languageItalian
Pages (from-to)431-432
Number of pages2
JournalRecenti Progressi in Medicina
Volume96
Issue number9
Publication statusPublished - Sep 2005

Fingerprint

RANK Ligand
Osteoprotegerin
Cytoplasmic and Nuclear Receptors
Osteopontin
Arthritis
Bone Remodeling
Ligands
Bone and Bones
Phosphoproteins
Osteoclasts
Serum
Vascular Smooth Muscle
Chemokines
Osteogenesis
Population
Smooth Muscle Myocytes
Enzyme-Linked Immunosorbent Assay
Macrophages
Students
T-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Il sistema RANKL/RANK, osteoprotegerina e osteopontina in una coorte di soggetti affetti da poliartrite cronica. Studio preliminare. / Minenna, Giovanna; D'Amore, Simona; Maggiolini, Piera; Scagliusi, Pasquale; D'Amore, Massimo.

In: Recenti Progressi in Medicina, Vol. 96, No. 9, 09.2005, p. 431-432.

Research output: Contribution to journalArticle

Minenna, Giovanna ; D'Amore, Simona ; Maggiolini, Piera ; Scagliusi, Pasquale ; D'Amore, Massimo. / Il sistema RANKL/RANK, osteoprotegerina e osteopontina in una coorte di soggetti affetti da poliartrite cronica. Studio preliminare. In: Recenti Progressi in Medicina. 2005 ; Vol. 96, No. 9. pp. 431-432.
@article{e87c2629f9484d5ca37c291140405ec8,
title = "Il sistema RANKL/RANK, osteoprotegerina e osteopontina in una coorte di soggetti affetti da poliartrite cronica. Studio preliminare",
abstract = "Recently, receptor activator of nuclear factor-kB ligand (RANKL), its receptor RANK, and the decoy receptor osteoprotegerin (OPG), have been identified as paracrine mediator of bone functions. The balance of RANKL/RANK and OPG is critical for osteoclastogenesis modulation and physiological bone remodeling. Osteopontin (OPN) is an extracellular glycosylate bone phosphoprotein and acts both as chemokine and cytochine. It is produced by osteoclast, macrophages, T cells, hematopoietic cells and vascular smooth muscle cells. It is present particularly at high concentration in the lamina limitans and cement line, suggesting its role in the initiation and termination of the bone turnover. Chronic arthritis are a group of rheumatic patologies characterized by periodical continuous or desultory use of corticosteroides. The main aims of this study are to valuate OPG, RANKL and OPN serum concentrations in patients affected by chronic arthritis and to compare the above results with those ones obtained by young healthy population. OPG, RANKL and OPN serum concentration has been measured by ELISA method both in 40 patients affected by chronic arthritis then in young healthy population of 81 subjects. The differences between the two considered groups have been analyzed using unpaired T-Student. The difference between the two groups is significant for considered variables: OPG: t=-6,54, p",
keywords = "Chronic arthritis, OPG, OPN, RANKL",
author = "Giovanna Minenna and Simona D'Amore and Piera Maggiolini and Pasquale Scagliusi and Massimo D'Amore",
year = "2005",
month = "9",
language = "Italian",
volume = "96",
pages = "431--432",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "9",

}

TY - JOUR

T1 - Il sistema RANKL/RANK, osteoprotegerina e osteopontina in una coorte di soggetti affetti da poliartrite cronica. Studio preliminare

AU - Minenna, Giovanna

AU - D'Amore, Simona

AU - Maggiolini, Piera

AU - Scagliusi, Pasquale

AU - D'Amore, Massimo

PY - 2005/9

Y1 - 2005/9

N2 - Recently, receptor activator of nuclear factor-kB ligand (RANKL), its receptor RANK, and the decoy receptor osteoprotegerin (OPG), have been identified as paracrine mediator of bone functions. The balance of RANKL/RANK and OPG is critical for osteoclastogenesis modulation and physiological bone remodeling. Osteopontin (OPN) is an extracellular glycosylate bone phosphoprotein and acts both as chemokine and cytochine. It is produced by osteoclast, macrophages, T cells, hematopoietic cells and vascular smooth muscle cells. It is present particularly at high concentration in the lamina limitans and cement line, suggesting its role in the initiation and termination of the bone turnover. Chronic arthritis are a group of rheumatic patologies characterized by periodical continuous or desultory use of corticosteroides. The main aims of this study are to valuate OPG, RANKL and OPN serum concentrations in patients affected by chronic arthritis and to compare the above results with those ones obtained by young healthy population. OPG, RANKL and OPN serum concentration has been measured by ELISA method both in 40 patients affected by chronic arthritis then in young healthy population of 81 subjects. The differences between the two considered groups have been analyzed using unpaired T-Student. The difference between the two groups is significant for considered variables: OPG: t=-6,54, p

AB - Recently, receptor activator of nuclear factor-kB ligand (RANKL), its receptor RANK, and the decoy receptor osteoprotegerin (OPG), have been identified as paracrine mediator of bone functions. The balance of RANKL/RANK and OPG is critical for osteoclastogenesis modulation and physiological bone remodeling. Osteopontin (OPN) is an extracellular glycosylate bone phosphoprotein and acts both as chemokine and cytochine. It is produced by osteoclast, macrophages, T cells, hematopoietic cells and vascular smooth muscle cells. It is present particularly at high concentration in the lamina limitans and cement line, suggesting its role in the initiation and termination of the bone turnover. Chronic arthritis are a group of rheumatic patologies characterized by periodical continuous or desultory use of corticosteroides. The main aims of this study are to valuate OPG, RANKL and OPN serum concentrations in patients affected by chronic arthritis and to compare the above results with those ones obtained by young healthy population. OPG, RANKL and OPN serum concentration has been measured by ELISA method both in 40 patients affected by chronic arthritis then in young healthy population of 81 subjects. The differences between the two considered groups have been analyzed using unpaired T-Student. The difference between the two groups is significant for considered variables: OPG: t=-6,54, p

KW - Chronic arthritis

KW - OPG

KW - OPN

KW - RANKL

UR - http://www.scopus.com/inward/record.url?scp=25144467885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144467885&partnerID=8YFLogxK

M3 - Articolo

VL - 96

SP - 431

EP - 432

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 9

ER -